LEO Pharma is progressing by leaps and bounds in the Chinese market by creating a subsidiary with the ambition of becoming the leading dermatological China.
The new company, LEO Pharma China, will market the broad portfolio of LEO Pharma of drugs protected by patents and high level for the treatment of chronic skin psoriasis and other dermatological products (pharmaceuticals for the treatment of skin diseases).
The leading brand for psoriasis LEO Pharma, Daivobet ®, has just been adopted by the Chinese authorities and can now be marketed in China.